Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease

被引：6
|
作者：
Al Sulais, Eman [1 ]
AlAmeel, Turki [2 ]
机构：
[1] Royal Commiss Hosp, Dept Med, POB 496, Jubail Ind City 31911, Qatif, Saudi Arabia
[2] King Fahad Specialist Hosp, Dept Med, Dammam, Saudi Arabia
来源：
BIOLOGICS-TARGETS & THERAPY | 2020年 / 14卷
关键词：
biosimilars; inflammatory bowel disease; tumor necrosis factor inhibitors; ACTIVE RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; DOUBLE-BLIND; INNOVATOR INFLIXIMAB; POSITION STATEMENT; ULCERATIVE-COLITIS; PARALLEL-GROUP; ANTIBODIES; EFFICACY; SAFETY;
D O I：
10.2147/BTT.S236433
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Health care providers ought to be aware of the available data that addresses the safety and efficacy of biosimilars in IBD patients. This article outlines the current evidence-based data regarding the available biosimilar products, their safety, efficacy and how to deal with patients' concerns.
引用
收藏
页码：1 / 11
页数：11
相关论文
共 50 条
  • [1] Antitumor necrosis factor treatment for pediatric inflammatory bowel disease
    de Bie, Charlotte I.
    Escher, Johanna C.
    de Ridder, Lissy
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (05) : 985 - 1002
  • [2] Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response
    Lichtenstein, Gary R.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2013, 6 (04): : 269 - 293
  • [3] Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
    Sandborn, WJ
    Hanauer, SB
    INFLAMMATORY BOWEL DISEASES, 1999, 5 (02) : 119 - 133
  • [4] Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease
    Salvador-Martin, Sara
    Bossacoma, Ferran
    Pujol-Muncunill, Gemma
    Navas-Lopez, Victor Manuel
    Gallego-Fernandez, Carmen
    Viada, Javier
    Munoz-Codoceo, Rosana
    Magallares, Lorena
    Martinez-Ojinaga, Eva
    Moreno-Alvarez, Ana
    Solar-Boga, Alfonso
    Segarra, Oscar
    Clemente, Susana
    Rodriguez-Martinez, Alejandro
    Alvarez-Vayo, Concepcion
    Loverdos, Ines
    Merino-Bohorquez, Vicente
    Balboa-Vega, Maria J.
    Blanca-Garcia, Jose A.
    Fobelo, Maria J.
    Millan-Jimenez, Antonio
    Garcia-Romero, Ruth
    Sanchez, Cesar
    Tolin, Mar
    Gonzalez de Caldas, Rafael
    Eizaguirre, Francisco J.
    Sanchez-Hernandez, Jose G.
    Torres-Peral, Ricardo
    Aznal, Elena
    Garcia-Gonzalez, Xandra
    Sanjurjo-Saez, Maria
    Lopez-Fernandez, Luis A.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 71 (04): : 508 - 515
  • [5] LOW RISK OF LYMPHOMA IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED USING ANTITUMOR NECROSIS FACTOR AGENTS
    Egberg, Matthew
    Smitherman, Andrew
    Zhang, Xian
    Kappelman, Michael
    GASTROENTEROLOGY, 2020, 158 (03) : S3 - S4
  • [6] Patient-Specific Approach to Combination Versus Monotherapy with the Use of Antitumor Necrosis Factor α Agents for Inflammatory Bowel Disease
    Devlin, Shane M.
    Cheifetz, Adam S.
    Siegel, Corey A.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2012, 41 (02) : 411 - +
  • [7] Black Inflammatory Bowel Disease Patients Have Lower Response to Antitumor Necrosis Factor Agents Compared With White Patients
    Burstiner, Landen Shane
    Owings, Anna H.
    Royer, Amor
    Hreish, Yousef
    Johnson, Jeshanah
    Barr, Madelyn
    Laird, Hannah
    Tarugu, Spurthi
    Edwards, Kane
    Bradley, Lauren
    Brar, Himmat
    Robinson, Tanya O.
    Hosseini-Carroll, Pegah
    Liu, Julia
    Glover, Sarah C.
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (12) : 1847 - 1853
  • [8] Anti-tumor Necrosis Factor Agents and Tuberculosis in Inflammatory Bowel Disease
    Yunho, Jung
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2020, 75 (01): : 1 - 3
  • [9] Biosimilars in inflammatory bowel disease
    Siegmund, B.
    Atreya, R.
    Bokemeyer, B.
    Kruis, W.
    Mudter, J.
    Sander, C.
    Schreiber, S.
    Reindl, W.
    Zeissig, S.
    Kucharzik, T.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2016, 54 (11): : 1217 - 1222
  • [10] Biosimilars in Inflammatory Bowel Disease
    Buchner, Anna M.
    Schneider, Yecheskel
    Lichtenstein, Gary R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (01): : 45 - 56
12345